查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864340

微生物組診斷市場按技術、診斷應用、檢體類型、適應症、最終用戶、服務類型和組件分類－2025-2032年全球預測

Microbiome Diagnostics Market by Technology, Diagnostic Application, Sample Type, Indication, End User, Service Type, Component - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，微生物組診斷市場將成長至 45.3031 億美元，複合年成長率為 21.39%。

關鍵市場統計數據
基準年 2024 9.6027億美元
預計年份：2025年 1,166,260,000 美元
預測年份 2032 4,530,310,000 美元
複合年成長率 (%) 21.39%

對微生物組診斷的精闢而全面的介紹揭示了技術整合和臨床檢驗為何正在重塑診斷診療路徑。

微生物組診斷領域融合了分子科學、臨床醫學和數位分析技術，正在革新疾病的檢測、分層和監測方式。近年來，技術進步降低了分析門檻，並拓展了可進行可靠分析的生物樣本範圍。同時，臨床和商業相關人員也日益認知到，微生物組既是診斷訊號的來源，也是治療標靶。因此，診斷流程正從單一分析物檢測發展為演算法驅動的多重評估方法，這些方法整合了生物學背景、患者病史和縱向監測數據。

生物資訊學和實驗室自動化領域的同步發展推動了這一演變，使高解析度分析更容易被診斷實驗室和研究機構所採用。儀器製造商、試劑供應商和軟體供應商之間日益密切的合作，正在加速端到端解決方案的開發，這些方案有望為臨床醫生提供更快的檢測結果、更高的可重複性和更具實用性的報告。監管機構和支付方正著手建立分析有效性、臨床效用和報銷途徑的框架，推動微生物組診斷從學術檢驗走向實際應用。總而言之，這些變化既為尋求規模化發展的機構帶來了即時的商業機遇，也帶來了中期營運挑戰。

快速的技術進步以及不斷變化的監管和商業模式將從根本上改變微生物組診斷的基礎設施和打入市場策略。

微生物組診斷領域正經歷著一場變革性的轉變，其驅動力包括技術的成熟、臨床的廣泛接受度以及經營模式的變革。定序和標靶擴增技術的進步使得從非侵入性檢體中提取更豐富、更具臨床意義的微生物特徵成為可能。這些技術進步與生物資訊學的進步相結合，將原始數據轉化為患者層面的解讀。因此，診斷開發人員越來越重視檢測設備、雲端分析和電子健康記錄之間的互通性，以確保結果在不同臨床環境中具有可重複性和可操作性。

同時，監管和報銷框架也在不斷發展，以應對基於微生物組的檢測的特異性特性，鼓勵企業儘早投資於臨床效用研究和支付方參與策略。這種監管重點，加上對個人化醫療日益成長的需求，正在推動診斷創新者、臨床研究機構和治療方法開發商之間更深入的合作。經營模式也在改變：集中式臨床實驗室和研究服務等服務型提案正在補充耗材和設備的銷售，從而創造混合收入來源和新的商業化路徑。這些趨勢正在重塑競爭優勢，並凸顯快速檢驗、品管和可擴展資料管理的重要性。

評估2025年關稅變化如何影響微生物組診斷相關人員的全球採購、供應鏈策略和採購決策

2025年實施的新關稅正在對支持微生物組診斷的整個供應鏈產生下游影響，尤其對那些依賴全球採購儀器、耗材和關鍵試劑的機構而言更是如此。關稅導致的成本增加，促使採購團隊重新評估其供應商配置和庫存策略，以降低進口關稅風險和前置作業時間波動的影響，加劇了採購營運的複雜性。因此，許多相關人員正在增加緩衝庫存並實現採購來源多元化，而這兩者都對企業的現金流量和實驗室產能規劃產生了影響。

為應對這些壓力，製造商和服務供應商正優先考慮受關稅影響最大的物流成本相關的零件，並考慮本地化生產和建立區域分銷中心。這種重組使得供應鏈透明度、品管和供應商選擇流程變得尤為重要，這些流程旨在檢驗不同供應商之間的效能等效性。同時，關稅也加速了耗材和檢體製備流程中價值工程的討論，以便在不影響檢測靈敏度或特異性的前提下減少材料用量。總而言之，這些調整正在影響資本配置、合約談判和策略聯盟，因為各機構需要在短期成本壓力和維持診斷可靠性及臨床信心的長期需求之間尋求平衡。

深度細分分析揭示了技術選擇、應用需求、檢體類型和最終用戶能力如何共同決定商業化路徑和臨床應用。

在微生物組診斷生態系統中，細分市場對於了解投資、創新和臨床應用將聚焦在哪些領域至關重要。基於技術的市場研究涵蓋微陣列、次世代定序和定量PCR (QPCR)，其中次世代定序進一步細分為16S rRNA定序、鳥槍法宏基因組學和全基因測序，而QPCR則細分為數位PCR和即時PCR。每種技術方法在分類解析度深度、週轉時間和單樣本成本方面各有優劣，這將決定其在臨床和研究領域的應用。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 人工智慧驅動的生物資訊平台在快速微生物組分析和預測診斷的應用日益廣泛
  • 新興的腸腦軸微生物組生物標記組合可用於神經系統疾病的早期檢測
  • 擴大照護現場，以實現分散式篩檢和病患監測。
  • 透過整合多體學（微生物組、代謝組和宿主基因組）數據加速精準診斷
  • 開發標準化的參考庫和工作流程，以確保微生物組診斷的可重複性
  • 消費者對在家中進行糞便和唾液微生物組檢測以獲得個人化營養和健康指導的興趣日益濃厚。
  • 診斷創新企業與製藥公司進行策略合作，共同開發微生物組伴隨診斷

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依技術分類的微生物組診斷市場

  • 微陣列
  • 次世代定序
    • 16S rRNA定序
    • 霰彈槍式宏基因體學
    • 全基因測序
  • 定量PCR
    • 數位PCR
    • 即時PCR

9. 按診斷應用分類的微生物組診斷市場

  • 疾病診斷
  • 藥物研發
    • 生物標記發現
    • 臨床試驗支持
  • 個人化營養
  • 風險評估
  • 治療監測

第10章 依檢體類型分類的微生物組診斷市場

  • 血
  • 航班
  • 口腔
  • 皮膚
  • 尿

第11章 依適應症分類的微生物組診斷市場

  • 皮膚病
  • 消化系統疾病
  • 感染疾病
  • 代謝性疾病
  • 腫瘤學

第12章 依最終用戶分類的微生物組診斷市場

  • 學術研究機構
  • 檢查機構
  • 醫院和診所
  • 製藥和生物技術公司

第13章 依服務類型分類的微生物組診斷市場

  • 臨床檢測服務
  • 研究服務

第14章 按組件分類的微生物組診斷市場

  • 消耗品
    • 套件和試劑
    • 樣品製備
  • 裝置
  • 軟體與生物資訊學
    • 雲端平台
    • 數據分析軟體
    • LIMS整合

第15章 各地區微生物組診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 按組別分類的微生物組診斷市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國微生物組診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Viome, Inc.
    • DayTwo, Inc.
    • CosmosID, Inc.
    • Microba Life Sciences Pty Ltd
    • Diversigen, Inc.
    • Microbial Insights, LLC
    • Admera Health LLC
    • Genova Diagnostics, Inc.
    • Omnibiome, LLC
    • BiomeSense Ltd
Product Code: MRR-BF5906741E57

The Microbiome Diagnostics Market is projected to grow by USD 4,530.31 million at a CAGR of 21.39% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 960.27 million
Estimated Year [2025] USD 1,166.26 million
Forecast Year [2032] USD 4,530.31 million
CAGR (%) 21.39%

An urgent and nuanced introduction to microbiome diagnostics illuminating why technological integration and clinical validation are redefining diagnostic care pathways

The microbiome diagnostics field sits at the confluence of molecular science, clinical medicine, and digital analytics, and it is reshaping how disease is detected, stratified, and monitored. Recent technological advances have reduced analytical barriers and expanded the range of biological samples that can be reliably profiled, while clinical and commercial stakeholders increasingly recognize the microbiome as both a source of diagnostic signal and a therapeutic target. As a result, diagnostic workflows are evolving from single-analyte tests to multiplexed, algorithm-driven assessments that integrate biological context with patient history and longitudinal monitoring.

This evolution is supported by parallel developments in bioinformatics and laboratory automation that make high-resolution profiling more accessible to diagnostic laboratories and research services. Increasing collaboration among instrument manufacturers, reagent suppliers, and software providers is accelerating end-to-end solutions that promise faster turnaround, improved reproducibility, and more actionable reports for clinicians. Regulatory authorities and payers are beginning to engage on frameworks for analytic validity, clinical utility, and reimbursement pathways, which is helping to move microbiome diagnostics beyond academic validation into real-world clinical adoption. Taken together, these shifts create both immediate commercialization opportunities and medium-term operational challenges for organizations trying to scale.

How rapid technological advances and shifting regulatory and commercial models are driving a fundamental transformation in microbiome diagnostics infrastructure and go-to-market strategies

The landscape for microbiome diagnostics is undergoing transformative shifts driven by technological maturation, broader clinical acceptance, and changing business models. Advances in sequencing modalities and targeted amplification are enabling richer, more clinically relevant microbial signatures to be derived from non-invasive samples, and this technical progress is coupled with greater sophistication in bioinformatics that translates raw data into patient-level interpretation. Consequently, diagnostic developers are increasingly prioritizing interoperability between laboratory instruments, cloud analytics, and electronic health records to ensure results are both reproducible and actionable across care settings.

Concurrently, regulatory and reimbursement frameworks are evolving to address the unique characteristics of microbiome-based tests, prompting companies to invest earlier in clinical utility studies and payer engagement strategies. This regulatory focus, together with rising demand for personalized care, is driving deeper collaboration between diagnostic innovators, clinical research organizations, and therapy developers. Business models are also shifting: service-oriented offerings such as centralized clinical testing services and research services are complementing product sales of consumables and instruments, creating hybrid revenue streams and new commercialization pathways. These dynamics are reshaping competitive advantages, emphasizing speed-to-validation, quality control, and scalable data management.

Assessment of how 2025 tariff changes are reshaping global sourcing, supply chain strategies, and procurement decisions for microbiome diagnostics stakeholders

The introduction of new tariff measures in 2025 has created downstream effects across supply chains that support microbiome diagnostics, particularly for organizations reliant on global sourcing of instruments, consumables, and critical reagents. Tariff-driven cost increases have amplified procurement complexity as purchasing teams reassess supplier footprints and inventory strategies to mitigate exposure to import duties and lead-time volatility. As a result, many stakeholders are increasing buffer stocks and seeking multi-sourcing arrangements, both of which influence operational cash flow and laboratory throughput planning.

In response to these pressures, manufacturers and service providers are exploring localized manufacturing or regional distribution hubs, prioritizing components whose logistics costs are most susceptible to tariff impact. This reconfiguration places a premium on supply chain transparency, quality management, and supplier qualification processes that validate performance parity across alternative sources. Simultaneously, tariffs have accelerated conversations about value engineering in consumables and sample preparation workflows to reduce material intensity without compromising assay sensitivity or specificity. Collectively, these adjustments are influencing capital allocation, contract negotiations, and strategic partnerships as organizations balance near-term cost pressures against the long-term imperative to maintain diagnostic reliability and clinical credibility.

Deep segmentation insights revealing how technology choices, application needs, sample types, and end-user capabilities collectively determine commercialization pathways and clinical adoption

Segment-level differentiation is central to understanding where investment, innovation, and clinical adoption will concentrate across the microbiome diagnostics ecosystem. Based on Technology, market studies encompass Microarray, Next-Gen Sequencing, and Qpcr, with Next-Gen Sequencing further divided into 16S Rrna Sequencing, Shotgun Metagenomics, and Whole Genome Sequencing, and Qpcr subdivided into Digital Pcr and Real-Time Pcr. Each technological pathway presents distinct trade-offs between depth of taxonomic resolution, turnaround time, and cost per sample, which in turn influence where they are deployed clinically and in research.

Based on Diagnostic Application, the landscape addresses Disease Diagnosis, Drug Development, Personalized Nutrition, Risk Assessment, and Therapeutic Monitoring, with Drug Development further studied across Biomarker Discovery and Clinical Trials Support; these application areas drive differing data requirements, regulatory expectations, and clinical validation pathways. Based on Sample Type, profiling of Blood, Fecal, Oral, Skin, and Urine samples requires tailored extraction and stabilization approaches that affect pre-analytic workflows and analytic performance. Based on Indication, focus across Dermatological Conditions, Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, and Oncology determines which biomarkers and assays are prioritized for clinical translation.

Based on End User, the market spans Academic Research Institutes, Diagnostic Laboratories, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies, each with distinct procurement cycles, technical capabilities, and data governance needs. Based on Service Type, offerings are classified as Clinical Testing Services and Research Services, which require different quality management systems and client engagement models. Based on Component, the ecosystem includes Consumables, Instruments, and Software & Bioinformatics, with Consumables further examined through Kits & Reagents and Sample Preparation, and Software & Bioinformatics decomposed into Cloud Platforms, Data Analysis Software, and LIMS Integration. Understanding the interplay among these segment dimensions clarifies why certain technologies are preferred in research versus clinical contexts, how sample type constraints shape assay design, and why end-user capabilities matter when selecting integrated solutions.

A nuanced regional analysis showing how regulatory frameworks, manufacturing capacity, and clinical ecosystems differ across the Americas, Europe Middle East & Africa, and Asia-Pacific and what that means for market entry

Regional dynamics are instrumental in shaping commercial priorities, regulatory engagement, and operational models across the microbiome diagnostics arena. In the Americas, vibrant venture funding, a concentration of clinical trial activity, and advanced laboratory infrastructure support rapid uptake of novel diagnostics, but the regulatory and reimbursement environment requires careful evidence generation focused on clinical utility and payer value. This region often sets commercial standards that influence global rollouts and partnership strategies.

In Europe, Middle East & Africa, heterogenous regulatory regimes and diverse healthcare financing models necessitate flexible go-to-market strategies that account for country-level differences in clinical practice and reimbursement mechanisms. Investment in centralized reference testing services and harmonized data standards can enable broader access across this region. In the Asia-Pacific region, fast-growing research capacity and domestic manufacturing initiatives are creating alternative production hubs and large-scale sample cohorts for validation studies. However, differences in data privacy frameworks, laboratory accreditation, and clinician adoption rates require localized evidence packages and tailored implementation plans. Across all regions, geopolitical factors, local supply chain capabilities, and talent availability will influence whether organizations prioritize local manufacturing, regional partnerships, or global distribution strategies.

Strategic competitive intelligence on how product integration, proprietary analytics, and collaborative partnerships define advantage in the microbiome diagnostics ecosystem

Competitive dynamics in microbiome diagnostics are defined less by a single dominant business model and more by complementary specialization across products, services, and analytics. Leading players tend to integrate strengths across consumables, instruments, and software, but differentiation increasingly comes from proprietary bioinformatics, validated clinical algorithms, and robust quality systems that support regulatory submissions. Companies that have invested in standardized sample preparation kits and interoperable cloud platforms are positioned to offer turn-key solutions that reduce barriers for diagnostic laboratories and clinical partners.

Partnerships and strategic alliances between reagent suppliers, instrument manufacturers, and analytics providers are accelerating time-to-market and increasing the availability of end-to-end validated workflows. At the same time, service providers that offer centralized clinical testing services provide an attractive path to clinical adoption for developers who prefer not to scale laboratory infrastructure. Competitive positioning also depends on the ability to demonstrate clinical utility in targeted indications and to support therapeutic development through biomarker discovery and clinical trial support. Intellectual property around assay chemistries, data processing pipelines, and clinical algorithms plays a moderating role in negotiations, and companies that build transparent validation dossiers and interoperable systems tend to secure broader clinical and commercial uptake.

Actionable recommendations to mitigate supply chain risk, build bioinformatics capability, and accelerate clinical validation while securing regulatory and payer alignment

Industry leaders should pursue a balanced set of strategic actions that address immediate operational constraints while positioning organizations for long-term clinical and commercial success. First, diversify sourcing and qualify alternative suppliers for key instruments and consumables to reduce tariff and logistics exposure, while implementing inventory optimization to smooth supply shocks. Second, invest substantively in bioinformatics capabilities and cloud-based analytics to convert complex microbial signatures into clinically interpretable outputs, and prioritize interoperability with electronic health systems and laboratory information management systems to facilitate adoption.

Third, engage early with regulatory bodies and payers to design evidence generation strategies that demonstrate clinical utility and economic value, and align clinical validation with intended use and reimbursement pathways. Fourth, pursue modular partnership models that combine centralized testing services with localized laboratory enablement, enabling rapid clinical access while building in-country diagnostic capacity. Fifth, standardize pre-analytic workflows and quality control to reduce variability across sample types such as blood, fecal, oral, skin, and urine, and develop companion documentation and training programs for end users including academic institutes, diagnostic laboratories, hospitals, and pharmaceutical companies. Finally, prioritize data governance, patient privacy, and transparent algorithm validation to build clinician trust and support deployment in sensitive indications such as oncology and infectious disease management.

Transparent and rigorous research methodology combining expert interviews, technical validation, regulatory review, and supply chain mapping to support defensible strategic conclusions

The research underpinning these insights combined primary and secondary enquiry methods to ensure balanced, verifiable conclusions. Primary input included structured interviews with clinical laboratory directors, research scientists, regulatory advisors, procurement officers, and commercial leaders to capture operational realities, validation hurdles, and adoption drivers across multiple geographies. These interviews were supplemented by expert panels that reviewed assay workflows, data pipelines, and quality management practices to validate technical assumptions and interpret clinical implications.

Secondary analysis encompassed peer-reviewed literature, regulatory guidance documents, patent landscapes, and public clinical trial registries to triangulate trends in assay development and indication-specific evidence requirements. Supply chain mapping and trade flow analysis were used to assess potential impacts of tariff changes on component sourcing and logistics. Data synthesis included thematic coding of qualitative interviews, cross-validation of technical performance claims, and scenario analysis to stress-test procurement and deployment strategies. Throughout the research process, findings were iteratively validated with subject-matter experts to ensure practical relevance and methodological rigor.

A concise conclusion summarizing the convergence of technology, clinical validation, and operational readiness that will determine which players lead in microbiome diagnostics

Microbiome diagnostics occupies a pivotal space in modern healthcare where molecular precision converges with clinical decision-making and personalized care pathways. Technological diversity-from targeted qPCR approaches to expansive whole genome and shotgun metagenomics-creates multiple viable routes for developers, each with distinct trade-offs in resolution, throughput, and clinical applicability. Adoption will be shaped by the ability to demonstrate clinical utility in meaningful indications, to manage pre-analytic variability across sample types, and to present reproducible analytics that clinicians and payers can trust.

Operational considerations such as supply chain resilience, regional regulatory nuances, and the maturity of local laboratory ecosystems will influence the pace and geography of adoption. Companies that align technical excellence with pragmatic commercialization strategies-combining validated workflows, interoperable analytics, and proactive regulatory engagement-will be best positioned to capture clinician mindshare and to partner effectively with pharmaceutical developers. In short, success will require cross-functional execution that bridges science, regulatory strategy, and commercial deployment in a coordinated manner.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of AI-powered bioinformatics platforms for rapid microbiome profiling and predictive diagnostics
  • 5.2. Emergence of gut-brain axis microbiome biomarker panels for early detection of neurological disorders
  • 5.3. Expansion of point-of-care microbiome testing devices enabling decentralized screening and patient monitoring
  • 5.4. Integration of multiomic microbiome, metabolomic, and host genomic data to advance precision diagnostics
  • 5.5. Development of standardized reference libraries and workflows to ensure reproducibility in microbiome diagnostics
  • 5.6. Rising consumer interest in at-home stool and saliva microbiome tests for personalized nutrition and wellness guidance
  • 5.7. Strategic partnerships between diagnostic innovators and pharma companies to co-develop microbiome companion diagnostics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Microbiome Diagnostics Market, by Technology

  • 8.1. Microarray
  • 8.2. Next-Gen Sequencing
    • 8.2.1. 16S Rrna Sequencing
    • 8.2.2. Shotgun Metagenomics
    • 8.2.3. Whole Genome Sequencing
  • 8.3. Qpcr
    • 8.3.1. Digital Pcr
    • 8.3.2. Real-Time Pcr

9. Microbiome Diagnostics Market, by Diagnostic Application

  • 9.1. Disease Diagnosis
  • 9.2. Drug Development
    • 9.2.1. Biomarker Discovery
    • 9.2.2. Clinical Trials Support
  • 9.3. Personalized Nutrition
  • 9.4. Risk Assessment
  • 9.5. Therapeutic Monitoring

10. Microbiome Diagnostics Market, by Sample Type

  • 10.1. Blood
  • 10.2. Fecal
  • 10.3. Oral
  • 10.4. Skin
  • 10.5. Urine

11. Microbiome Diagnostics Market, by Indication

  • 11.1. Dermatological Conditions
  • 11.2. Gastrointestinal Disorders
  • 11.3. Infectious Diseases
  • 11.4. Metabolic Disorders
  • 11.5. Oncology

12. Microbiome Diagnostics Market, by End User

  • 12.1. Academic Research Institutes
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals & Clinics
  • 12.4. Pharmaceutical & Biotechnology Companies

13. Microbiome Diagnostics Market, by Service Type

  • 13.1. Clinical Testing Services
  • 13.2. Research Services

14. Microbiome Diagnostics Market, by Component

  • 14.1. Consumables
    • 14.1.1. Kits & Reagents
    • 14.1.2. Sample Preparation
  • 14.2. Instruments
  • 14.3. Software & Bioinformatics
    • 14.3.1. Cloud Platforms
    • 14.3.2. Data Analysis Software
    • 14.3.3. LIMS Integration

15. Microbiome Diagnostics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Microbiome Diagnostics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Microbiome Diagnostics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Viome, Inc.
    • 18.3.2. DayTwo, Inc.
    • 18.3.3. CosmosID, Inc.
    • 18.3.4. Microba Life Sciences Pty Ltd
    • 18.3.5. Diversigen, Inc.
    • 18.3.6. Microbial Insights, LLC
    • 18.3.7. Admera Health LLC
    • 18.3.8. Genova Diagnostics, Inc.
    • 18.3.9. Omnibiome, LLC
    • 18.3.10. BiomeSense Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. MICROBIOME DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. MICROBIOME DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MICROBIOME DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY 16S RRNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY 16S RRNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY 16S RRNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY 16S RRNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY 16S RRNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY 16S RRNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SHOTGUN METAGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SHOTGUN METAGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SHOTGUN METAGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SHOTGUN METAGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SHOTGUN METAGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SHOTGUN METAGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DISEASE DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DISEASE DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DISEASE DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DISEASE DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DISEASE DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DISEASE DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PERSONALIZED NUTRITION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PERSONALIZED NUTRITION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PERSONALIZED NUTRITION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PERSONALIZED NUTRITION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PERSONALIZED NUTRITION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PERSONALIZED NUTRITION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY FECAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY FECAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY FECAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY FECAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY FECAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY FECAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SKIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SKIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SKIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SKIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SKIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SKIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RESEARCH SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RESEARCH SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RESEARCH SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RESEARCH SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RESEARCH SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RESEARCH SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLOUD PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLOUD PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLOUD PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLOUD PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLOUD PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLOUD PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY LIMS INTEGRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY LIMS INTEGRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY LIMS INTEGRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY LIMS INTEGRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY LIMS INTEGRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY LIMS INTEGRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (